Israel's Gilat Satellite misses Q3 revenue estimates; says launch delays, contract timing hit forecast

By Reuters News


Overview

  • Israel satellite communications firm's Q3 revenue declined yr/yr and missed analyst expectations

  • Adjusted EBITDA rose 13% and non-GAAP net income increased 21% in Q3

  • Profitability improved despite weaker currency and bad debt write-offs


Outlook

  • Gilat revises 2026 revenue to between $455 mln and $475 mln

  • Company cites delayed satellite launches and Peru contract timing as factors impacting 2026 revenue outlook

  • Company expects 2026 adjusted EBITDA between $61 mln and $63 mln


Result Drivers

  • COST AND PRICING DISCIPLINE - Co said improved profitability was driven by cost and pricing discipline, despite weaker currency and bad debt write-offs

  • DEFENSE SEGMENT GROWTH - Defense segment revenue grew 53% yr/yr, contributing to overall results

  • DELAYS AND REVENUE SHIFT - Co cited rescheduled terminal deliveries, satellite launch delays, and later-than-expected Peru agreements as factors shifting revenue timing


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$116.23 mln

$126.65 mln (3 Analysts)

Q3 Net Income

$8.67 mln

Q3 Gross Profit

$40.80 mln

Q3 Operating Expenses

$32.90 mln

Q3 Operating Income

$7.91 mln

Q3 Pretax Profit

$9.80 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the communications & networking peer group is "buy"

  • Wall Street's median 12-month price target for Gilat Satellite Networks Ltd. is $19.20, about 153.3% above its November 9 closing price of $7.58

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 16 three months ago


Reuters Recommended Reads

  • Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

  • Nov 9 - Israel's Monday.com Q3 revenue rises 19%

  • Nov 10 - Israel's Protalix BioTherapeutics Q3 revenue rises, driven by higher sales to Chiesi


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.